Clinical Trial Update: Immunomodulation of EA-230 Following On-pump Coronary Artery Bypass Grafting (CABG) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating immunomodulation with EA-230 following on-pump coronary artery bypass grafting for systemic inflammatory response syndr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Inflammatory Response Syndrome

Drugs mentioned

• EA-230 (EA-230)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Systemic Inflammatory Response Syndrome, Coronary Artery Bypass Grafting | Phase 2 | Status: UNKNOWN